Dynavax's Hepatitis B vaccine Hepislav has the opportunity to bounce back; a first review is positive but there is a ways to go.

In this interview with The Life Sciences Report, Vernon Bernardino of MLV & Co. brings some clarity and perspective to investors who could reap windfalls from small-cap names in which shareholder value has yet to be created and realized.